Munich trial will pair tirzepatide weight loss with a closer look at cognition and food noise
A new ancillary study in Munich is asking a question obesity medicine has largely left on the margins: what happens to the brain, daily function, and food-related thinking when substantial weight loss is driven by tirzepatide and paired with resistance training? RESIST-MIND is designed around adults with obesity enrolled in the parent RESIST trial, where participants receive tirzepatide and are randomized to structured resistance training or usual care over 24 weeks. The ancillary study itself adds no drug, no exercise prescription, and no new biological sampling. Its value lies in measurement discipline, not intervention novelty.
The focus is unusually bedside-relevant. Patients who lose weight quickly often describe less energy, difficulty concentrating, disrupted sleep, and a persistent mental preoccupation with food. Those symptoms are rarely captured with the same rigor as weight change or body composition, even though they can shape adherence, work performance, and long-term maintenance. RESIST-MIND is built to assess whether preserving lean mass and strength during pharmacologic weight loss may track with better attention, less fatigue, and fewer intrusive food thoughts.
What the ancillary study will measure at week 0 and week 24
RESIST-MIND is a prospective, monocentric observational cohort study conducted at TUM Klinikum in Munich. Participants complete questionnaires and an electronic attention test at baseline and again at the end of the 24-week treatment period. The study uses validated instruments for multiple domains: concentration performance and processing speed with the d2-R Test of Attention; fatigue with the MFI-20; sleep quality with the PSQI; general functioning with the WHODAS 2.0 12-item scale; food-related cognition with the FNQ; trait food craving with the FCQ-T-reduced; and a scale for self-stigma related to obesity. In working participants, work ability and work productivity are also assessed through WAI and WPAI measures.
The design keeps the ancillary study tightly tethered to data already being collected in RESIST. Muscle mass, strength, body composition, anthropometrics, and patient-reported variables come from the parent trial database rather than from additional procedures. Endpoints are exploratory and equally ranked, all defined as change from week 0 to week 24. No formal power calculation and no multiplicity adjustment are planned, which is appropriate for an observational substudy meant to generate signals rather than confirm efficacy.
One sentence captures the entire architecture: no extra visits, no extra intervention, no extra sample burden.
Why resistance training may matter during pharmacologic weight loss
The biological rationale is straightforward. Tirzepatide can drive clinically meaningful weight loss, but weight loss is not automatically synonymous with preservation of functional capacity. During caloric deficit, skeletal muscle can be lost along with adipose tissue, and reduced muscle mass may feed into fatigue, lower exercise tolerance, and diminished day-to-day vigor. Resistance training offers a plausible counterweight by preserving or improving muscle strength and body composition while the medication reduces appetite and energy intake. In theory, this combination could help patients lose weight without paying for it in physical performance or mental sharpness.
The trial’s attention to food craving and “food noise” is equally important. Appetite suppression may reduce the intensity of food-related thoughts, yet the psychological experience of dieting is not determined by hunger alone. Habit loops, reward salience, and stress-related eating can persist even when pharmacologic satiety is high. By measuring food-related cognition and craving alongside objective attention testing, RESIST-MIND is trying to determine whether the exercise arm influences the cognitive burden of weight loss itself.
Fatigue and sleep quality belong in the same framework. Obesity, insufficient sleep, and low physical activity frequently cluster, and each can worsen the others. If resistance training improves sleep or lowers fatigue during tirzepatide therapy, the downstream effect could be broader than improved gym performance. Better sleep and less fatigue may support adherence to diet counseling, physical activity, and workplace functioning, especially in a population still navigating a 24-week structured weight-loss program.
The parent RESIST trial supplies the intervention contrast
Participants enter RESIST-MIND only if they are provisionally eligible for randomization in the parent RESIST trial and provide written informed consent for the ancillary study. RESIST itself is a randomized, controlled, open-label Phase IV trial in 150 adults with obesity. The parent protocol compares structured resistance training with usual care while all participants receive tirzepatide over 24 weeks, alongside individualized diet and physical activity counseling.
The resistance training program is machine-based, progressive, and supervised when feasible. It begins with an acclimation phase during weeks 1 through 4, then moves into a target phase from weeks 5 through 24 using roughly 8 to 12 repetitions at about 70% to 75% of one-repetition maximum, with additional eccentric overload introduced from week 9. Sessions are intended to occur about three times per week. The usual care arm receives tirzepatide and counseling without the structured training program. RESIST-MIND does not alter that assignment; it observes the consequences of being in one arm or the other.
Explaining the planned analyses without overpromising the answer
Investigators plan to estimate between-group differences with linear models adjusted for baseline values. They also plan to examine whether changes in body composition relate to changes in the ancillary endpoints across both groups using correlation and multiple linear regression. Those analytic choices fit the study’s exploratory intent. They allow the team to ask whether a better body composition profile accompanies better attention, less fatigue, or lower food craving, while stopping short of claiming causality from an ancillary dataset that was never built for definitive inference.
The absence of a formal power calculation is a real constraint, but it is not a flaw for a study framed as observational and hypothesis-generating. A small, carefully phenotyped cohort can still provide clinically useful direction, especially when the outcomes are patient-centered and mechanistically linked. If resistance training appears to preserve cognition or reduce the subjective strain of weight loss, that would support future trials that place function and daily experience on equal footing with the scale.
Who the study is trying to understand
Eligibility is limited to adults aged 18 to 60 years with obesity, defined here as BMI of at least 30 kg/m², without manifest type 2 diabetes or structural cardiovascular disease, and with sufficient German language ability. Participants must also be appropriate candidates for the parent trial’s pharmacologic and exercise framework. The study excludes anyone not randomized into RESIST for any reason, which keeps the ancillary cohort aligned with the parent randomization structure.
This is a narrow population, and the narrowness is intentional. The findings will speak most directly to adults with obesity who are healthy enough for structured exercise and pharmacologic weight loss, not to every patient seen in an obesity clinic. Even so, the questions are clinically sharp. Can resistance training preserve more than muscle during tirzepatide treatment? Does it alter attention, functioning, or food craving in ways patients can feel? And do those changes travel with body composition rather than simply with kilograms lost?
RESIST-MIND begins in October 2026 and is expected to complete in July 2027. The study will not answer every question about how obesity drugs interact with the brain or behavior, but it is set up to address one of the most practical ones: whether the way patients lose weight changes how they think, work, sleep, and function while they are losing it.